Trial Profile
Phase 2 study of amrubicin plus bevacizumab in patients with previously treated advanced non-sq NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Mar 2014 New trial record